MA -based Homology Medicines has raised $144 million in an initial public offering to help fund its first clinical trials. The company claims to have a superior version of existing gene-editing methods, including Homology Medicines , by making use of a natural biological process called homologous recombination by which body cells repair DNA damage. Frank Vinluan is an Xconomy editor based in Research Triangle Park. Homology is also developing gene therapies that use adeno-associated viruses (gene therapy delivery tools) developed in-house. The company's first clinical trials will target the genetic disorder phenylketonuria, initially in adults and then later this year in children.
MA -based Homology Medicines has raised $144 million in an initial public offering to help fund its first clinical trials. The company claims to have a superior version of existing gene-editing methods, including Homology Medicines , by making use of a natural biological process called homologous recombination by which body cells repair DNA damage. Homology is also developing gene therapies that use adeno-associated viruses (gene therapy delivery tools) developed in-house. The company's first clinical trials will target the genetic disorder phenylketonuria, initially in adults and then later this year in children.